As of 6 Nov 2026, Panacea Biotec is loss-making on a trailing 12-month basis, with a net loss of ₹7.12 Cr, so it has no P/E ratio. The share price is ₹344.00, 47% below its 52-week high. Sales grew 10% a year over 3 years. It carries very little debt. It is a small-cap company with a market cap of ₹2,102 Cr, ranked 9th of 20 Biotechnology companies by market cap; the shares fell 18% over the past year.
- ₹355.00
- ₹355.05
- ₹342.80
- ₹354.75
- 32.6K
Health check
- ReturnsBehind
−17.9% over a year, better than 1 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +10.1% a year over 3 years, but loss-making now.
- ProfitabilityNegative
ROCE -0.2% vs peer median 16.7%.
- Balance sheetStretched
Practically debt-free.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹2,102 Cr
- Small cap
- P/E
- n/a
- Industry 49.1
- Price to book
- 2.68
- Peers 4.68
- Dividend yield
- 0.00%
- ROE
- −0.6%
- Peers 14.3%
- ROCE
- −0.2%
- Peers 16.7%
- Debt to equity
- 0.03
- Debt ₹24 Cr
- EPS (TTM)
- −₹1.16
- Face value ₹1
- OPM (TTM)
- 0.3%
- Net margin −1.1%
- Sales growth
- +19.7%
- Latest quarter vs a year ago
- Profit growth
- −43.2%
- Latest quarter vs a year ago
- Price to sales
- 3.13
- EV/EBITDA 700.5
Strengths and risks
Strengths
- Practically debt-free.
- Quarterly sales up 19.7% on a year ago.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −0.6%.
- Quarterly profit down 43.2% on a year ago.
- 47% below its 52-week high.
- Interest coverage of only 0.1×.
About Panacea Biotec
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. The company operates through Vaccines and Pharmaceutical Formulations & Nutrition segments. Its product portfolio includes prescription products in various therapeutic areas, such as diabetes, gastro-intestinal care,…
- Headquarters
- New Delhi
- Employees
- 2,102
- Sector
- Healthcare
- ISIN
- INE922B01023
- Website
- panaceabiotec.com
Price range
- Avg volume (3M)
- 94.5K
- 1-year return
- minus 17.9%
- From 52-week high
- minus 46.8%
Peers · Biotechnology
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOCONBiocon | 365.10 | plus 0.86% | 59,794 | 122.5 | 1.73 | 2.8% | 1.0% | 20.5% | 15.3% | −5.9% | 0.14% | minus 4.9% |
| ANTHEMAnthem Biosciences | 915.55 | plus 0.22% | 51,594 | 84.6 | 15.74 | 26.8% | 20.4% | 41.4% | 26.2% | 15.4% | 0.22% | plus 30.1% |
| ONESOURCEOnesource Specialty Pharma | 1,599.80 | plus 1.13% | 18,346 | – | 3.10 | 0.3% | 0.0% | 23.5% | 232.3% | – | 0.00% | minus 13.7% |
| CONCORDBIOConcord Biotech | 632.60 | minus 5.96% | 13,236 | 47.4 | 6.48 | 16.7% | 14.3% | 34.5% | 8.0% | 2.8% | 0.56% | minus 7.5% |
| BLUEJETBlue Jet Healthcare | 553.80 | minus 3.91% | 9,607 | 34.5 | 4.52 | 24.0% | 19.9% | 31.4% | 9.4% | 15.7% | 0.21% | minus 5.0% |
| SUPRIYASupriya Lifescience | 695.80 | minus 19.99% | 5,600 | 28.2 | 4.68 | 22.3% | 19.1% | 21.4% | 21.2% | 32.5% | 0.11% | plus 9.2% |
| ZOTAZota Health Care | 1,231.10 | plus 1.01% | 4,264 | – | 6.82 | −7.3% | −24.1% | 0.1% | 56.7% | – | 0.08% | minus 21.9% |
| PANACEABIOPanacea Biotec | 344.00 | minus 3.03% | 2,102 | – | 2.68 | – | −0.9% | −1.1% | 10.1% | – | 0.00% | minus 17.9% |
| Median of 7 peers | – | 0.22% | 13,236 | 47.4 | 4.68 | 16.7% | 14.3% | 23.5% | 21.2% | 15.4% | 0.14% | −5.0% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 167 | 141 | 165 | 167 | 200 | |
| 168 | 159 | 153 | 164 | 194 | |
| −1.2 | −17.8 | 11.7 | 2.6 | 5.7 | |
| −0.7% | −12.6% | 7.1% | 1.5% | 2.8% | |
| 5.7 | 6.4 | 2.3 | 2.6 | 4.2 | |
| 0.9 | 2.1 | 1.9 | 1.2 | 1.2 | |
| 8.4 | 8.3 | 8.5 | 7.9 | 7.9 | |
| 11.3 | 2.7 | 2.8 | 2.7 | 2.7 | |
| 6.6 | −19.2 | 6.5 | −1.3 | 3.6 | |
| 39.6% | 26.9% | 40.1% | 20.0% | 38.4% | |
| 4.1 | −13.9 | 4 | 0.5 | 2.3 | |
| 0.66 | -2.27 | 0.65 | 0.08 | 0.38 |
Profit & loss
- Sales CAGR 3Y
- +10.1%
- ROE
- −0.6%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 457 | 552 | 493 | 610 | |
| – | +20.8% | minus 10.7% | +23.8% | |
| 523 | 559 | 513 | 610 | |
| −66.5 | −7.5 | −20.8 | 0.4 | |
| −14.6% | −1.4% | −4.2% | 0.1% | |
| 16.8 | 14.4 | 13.2 | 10.4 | |
| 3.8 | 2.7 | 2.9 | 5.4 | |
| 39.1 | 36.7 | 34.8 | 33.1 | |
| 105 | 34 | 37.4 | 20.3 | |
| 12.8 | 1.5 | −7.9 | −7.4 | |
| 363.5% | 201.9% | −9.7% | 2.8% | |
| −33.2 | −1.2 | −8.4 | −5.4 | |
| -5.43 | -0.19 | -1.37 | -0.88 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 6.1 | 6.1 | 6.1 | 6.1 | |
| 837 | 836 | 829 | 829 | |
| 20.2 | 15 | 15 | 15 | |
| 407 | 384 | 440 | 412 | |
| 1,271 | 1,241 | 1,290 | 1,262 | |
| 623 | 636 | 641 | 654 | |
| 35 | 76.3 | 97.4 | 101 | |
| 3.7 | 1 | 3.1 | 7.5 | |
| 213 | 174 | 123 | 127 | |
| 396 | 353 | 426 | 372 | |
| 1,271 | 1,241 | 1,290 | 1,262 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −422 | 3.5 | −27.4 | 16.7 | |
| 430 | 6.7 | 65 | −40.5 | |
| −18.4 | −2.8 | −2.7 | −1.1 | |
| −10.5 | 7.3 | 35 | −24.9 | |
| −40.9 | −82.9 | −50.3 | −54.1 | |
| −463 | −79.4 | −77.7 | −37.4 |
Shareholding pattern
- Promoters72.48%
- Public27.52%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 72.48% | 27.52% | 0.00 | |
| 30 Jun 2026 | 72.48% | 27.52% | 0.00 | |
| 31 Mar 2026 | 72.48% | 27.52% | 0.00 | |
| 31 Dec 2025 | 72.48% | 27.52% | 0.00 | |
| 30 Sep 2025 | 72.48% | 27.52% | – |
Major shareholders
Filings & events
News
No recent news coverage found.